Literature DB >> 16937533

On attitudes about colorectal cancer screening among gastrointestinal specialists and general practitioners in the Netherlands.

J S Terhaar Sive Droste1, G D N Heine, M E Craanen, H Boot, C J J Mulder.   

Abstract

AIM: To find out whether there are differences in attitudes about colorectal cancer (CRC) screening among gastrointestinal (GI) specialists and general practitioners (GPs) and which method is preferred in a national screening program.
METHODS: Four hundred and twenty Dutch GI specialists in the Netherlands and 400 GPs in Amsterdam were questioned in 2004. Questions included demographics, affiliation, attitude towards screening both for the general population and themselves, methods of screening, family history and individual risk.
RESULTS: Eighty-four percent of the GI specialists returned the questionnaire in comparison to 32% of the GPs (P < 0.001). Among the GI specialists, 92% favoured population screening whereas 51% of GPs supported population screening (P < 0.001). Of the GI specialists 95% planned to be screened themselves, while 30% of GPs intended to do so (P < 0.001). Regarding the general population, 72% of the GI specialists preferred colonoscopy as the screening method compared to 27% of the GPs (P < 0.001). The method preferred for personal screening was colonoscopy in 97% of the GI specialists, while 29% of the GPs favoured colonoscopy (P < 0.001).
CONCLUSION: Screening for CRC is strongly supported by Dutch GI specialists and less by GPs. The major health issue is possibly misjudged by GPs. Since GPs play a crucial role in a successful national screening program, CRC awareness should be realized by increasing knowledge about the incidence and mortality, thus increasing awareness of the need for screening among GPs.

Entities:  

Mesh:

Year:  2006        PMID: 16937533      PMCID: PMC4088020          DOI: 10.3748/wjg.v12.i32.5201

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial.

Authors:  J H Scholefield; S Moss; F Sufi; C M Mangham; J D Hardcastle
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

2.  Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.

Authors:  J F Helm; M W Russo; A K Biddle; K N Simpson; D F Ransohoff; R S Sandler
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

3.  Colorectal cancer screening in Europe: first things first.

Authors:  J W W Coebergh
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

4.  Survey of primary physicians' knowledge of colorectal cancer screening.

Authors:  Shlomo Birkenfeld; Yaron Niv
Journal:  J Clin Gastroenterol       Date:  2006-01       Impact factor: 3.062

5.  The effect on compliance of a health education leaflet in colorectal cancer screening in general practice in central England.

Authors:  A R Hart; T L Barone; S P Gay; A Inglis; L Griffin; C A Tallon; J F Mayberry
Journal:  J Epidemiol Community Health       Date:  1997-04       Impact factor: 3.710

6.  Would general practitioners support a population-based colorectal cancer screening programme of faecal-occult blood testing?

Authors:  S Tong; K Hughes; B Oldenburg; C Del Mar
Journal:  Intern Med J       Date:  2004 Sep-Oct       Impact factor: 2.048

7.  Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.

Authors:  Beth A O'Leary; John K Olynyk; A Munro Neville; Cameron F Platell
Journal:  J Gastroenterol Hepatol       Date:  2004-01       Impact factor: 4.029

8.  Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability.

Authors:  Mario Hermsen; Cindy Postma; Jan Baak; Marjan Weiss; Anna Rapallo; Andrea Sciutto; Guido Roemen; Jan-Willem Arends; Richard Williams; Walter Giaretti; Anton De Goeij; Gerrit Meijer
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

9.  Factors affecting compliance in colorectal cancer screening. Results of a study performed in Ballarat.

Authors:  F A Macrae; D J St John; A Ambikapathy; K Sharpe; J F Garner
Journal:  Med J Aust       Date:  1986-06-09       Impact factor: 7.738

10.  Screening for symptomless colorectal cancer by testing for occult blood in general practice.

Authors:  J D Hardcastle; T W Balfour; S S Amar
Journal:  Lancet       Date:  1980-04-12       Impact factor: 79.321

View more
  4 in total

1.  Colorectal cancer screening perceptions and practices: results from a national survey of gastroenterology, surgery and radiology trainees.

Authors:  Amy S Oxentenko; Robert A Vierkant; Darrell S Pardi; David R Farley; Eric J Dozois; Thomas E Hartman; David M Hough; Wesley O Petersen; Carrie N Klabunde; Katherine Sharpe; John H Bond; Robert A Smith; Bernard Levin; John B Pope; Paul C Schroy; Paul J Limburg
Journal:  J Cancer Educ       Date:  2007       Impact factor: 2.037

2.  Awareness and attitudes of Greek medical students on colorectal cancer screening.

Authors:  Ioannis S Papanikolaou; Athanasios D Sioulas; Stylianos Kalimeris; Persephone Papatheodosiou; Ioannis Karabinis; Olga Agelopoulou; Iosif Beintaris; Dimitrios Polymeros; George Dimitriadis; Konstantinos Triantafyllou
Journal:  World J Gastrointest Endosc       Date:  2012-11-16

3.  The use of registered nurses to perform flexible sigmoidoscopy procedures in ontario: a cost minimization analysis.

Authors:  Sarah E Costa; Peter C Coyte; Audrey Laporte; Laura Quigley; Shannon Reynolds
Journal:  Healthc Policy       Date:  2012-02

4.  Colorectal cancer screening behaviors of general surgeons and first-degree family members: a survey-based study.

Authors:  Suleyman Utku Celik; Hasan Gorkem Cay; Ersin Bayrakdar; Aysima Ince; Esra Nur Ince; Yasemin Celik; Yunus Emre Yucel; Mehmet Ali Koc; Siyar Ersoz; Cihangir Akyol
Journal:  BMC Gastroenterol       Date:  2019-11-12       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.